Ann: Pause in Trading, page-14

Cash position as at end of March 2022 was $8.6M, with sufficient cash and significant global partnering opportunities anticipated to generate revenue, supporting future cash flow• Confirmed ~$5M cash receipts from revenues for balance of calendar year 2022, excluding any potential partnering deals Medlab is currently working on• 70+ partnering engagements to which five partnership agreements are in discussions/term sheet generation

Stated in last quarterly (as little as 2 months ago) they had sufficient cash and significant global partnering opportunities...... 2 months later sell the company down to 4.1c to raise capital at an all time low.......